Next, we investigated the role of the M0RGs signature in predicting ICI therapeutic efficacy in HCC by evaluating the relationship between six well-known ICI targets, including CTLA-4, PD-1, PD-L1, IDO1, TIM-3, and PD-L2. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.